Begin main content

What does the evidence say about COVID-19?

April 2, 2020
CADTH is here to answer your questions about COVID-19. We’ve collected relevant information from CADTH and other respected organizations and published it on our new CADTH/COVID-19 web portal. On this site, you’ll find evidence, tools, and resources covering a range of COVID-19 topics including prevention, testing, and treatment. Although some ...

Patient Input and Clinical Experts: Luxturna

March 25, 2020
CADTH has received the following notice(s) of pending drug submission(s). Brand name Luxturna Generic name voretigene neparvovec Manufacturer Novartis Pharmaceuticals Canada Inc. Indication(s) Vision loss, inherited retinal dystrophy Project Number SR0643-000 Call for patient ...

COVID-19: An Update From Dr. Brian O’Rourke, CADTH President and CEO

March 18, 2020
For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada. As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period. Public health authorit...

Drug Reimbursement Recommendation - tafamidis (Vyndaqel)

February 21, 2020
Today, CADTH has issued final recommendations for: tafamidis (Vyndaqel) Indications: transthyretin-mediated amyloidosis Recommendation: Reimburse with clinical criteria and/or conditions For more information